Katie Lai, associate director of Medpace Taiwan, introduces the company’s history in Taiwan and highlights the CRO’s unique service offering as a partner of choice to the biotech sector. Lai goes on to give her expert insights in the evolving clinical research environment of Taiwan and the APAC region.
Rare diseases are a very important area for us. It is very meaningful for me to try to find medications which can actually contribute to improving the lives of patients and their caretakers.
